
Experts unpack evolving neoadjuvant and adjuvant strategies for high‑risk HER2+ early breast cancer, from TCHP to T-DM1, T-DXd, and neratinib.
This OncLive News Network program explores evolving treatment strategies for patients with HER2-positive early breast cancer, with a focus on translating emerging clinical trial evidence into clinical practice. Dr. Ruta Rao and Dr. Jason Mouabbi discuss the current treatment continuum from neoadjuvant therapy through surgery and post-neoadjuvant treatment, including the role of pathologic response in guiding subsequent management. They review findings from the DESTINY-Breast11 trial and consider how its high-risk study population relates to the broader FDA-approved neoadjuvant indication and current NCCN recommendations. The discussion then moves to the post-neoadjuvant setting, comparing the high-risk population and findings from DESTINY-Breast05 with the established evidence from KATHERINE, including considerations for T-DXd and T-DM1 selection. Dr. Rao and Dr. Mouabbi also discuss treatment sequencing, individual patient selection, and practical considerations surrounding T-DXd-associated interstitial lung disease, emphasizing the importance of monitoring and multidisciplinary coordination when treating HER2-positive early breast cancer.

Experts unpack evolving neoadjuvant and adjuvant strategies for high‑risk HER2+ early breast cancer, from TCHP to T-DM1, T-DXd, and neratinib.

Dr. Ruta Rao reviews the design and key findings of DESTINY-Breast11 in patients with high-risk HER2-positive early breast cancer receiving neoadjuvant therapy.

Dr. Jason Mouabbi discusses how the broader FDA neoadjuvant indication for HER2-positive early breast cancer may be interpreted in clinical practice relative to the more narrowly defined high-risk population enrolled in DESTINY-Breast11.

Dr. Jason Mouabbi discusses the design and patient population of DESTINY-Breast05 in the post-neoadjuvant setting for HER2-positive early breast cancer, highlighting key distinctions from the broader KATHERINE study population.

Dr. Jason Mouabbi discusses the evolving roles of T-DXd and T-DM1 in the post-neoadjuvant management of HER2-positive early breast cancer following the DESTINY-Breast05 findings.

Dr. Jason Mouabbi and Dr. Ruta Rao discuss balancing the efficacy of T-DXd with safety considerations in the treatment of HER2-positive early breast cancer, with particular emphasis on interstitial lung disease (ILD) in the curative setting.